Xilio Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Xilio Therapeutics, Inc. (XLO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $7.70 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- Xilio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $7.70, a 1162.30% increase year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.61.
- Xilio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.69, a 54.33% decline year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-03-31 was $5.89.
- Xilio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $8.28, a 1405.45% increase from fiscal 2024.
- Xilio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $0.55, a 80.50% decline from fiscal 2023.
- Xilio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $2.82, a 52.12% decline from fiscal 2022.
- Xilio Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $5.89, a 0.17% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.70 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $7.70 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $8.28 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $0.58 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $0.59 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $0.61 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $0.55 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $0.55 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $0.55 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | $2.82 10-K · filed 2024-04-01 | |||
| 2023-09-30 | $2.82 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $2.69 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $2.69 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $5.89 10-K · filed 2023-03-02 | |||
| 2022-09-30 | $5.89 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $5.89 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $5.89 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $5.90 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $5.55 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |